MTPConnect – Connecting to Australia’s Thriving Life Sciences Sector
MTPConnect is Australia’s Life Sciences Innovation Accelerator – an independent, not-for-profit organisation established by the Australian Government to champion the continuing growth of Australia’s vibrant medical products sector.
MTPConnect’s focus is taking cutting-edge research from bench to bedside by working collaboratively with all parts of Australia’s medical technology, biotechnology and pharmaceutical sector; from universities and medical research institutes to start-ups and small to medium sized enterprises to listed companies, and governments, policy makers and regulators.
MTPConnect designs and delivers accelerator, sector building and workforce programs for Australian Government agencies and state governments. It co-funds cutting edge innovation and research projects, supports expansion of the clinical trials ecosystem, develops workforce commercialisation skills and represents the Australian sector with a strong and independent voice to promote connections to international markets and improve access to global supply chains. .
MTPConnect operates the industry-led Australian Antimicrobial Resistance Network – AAMRNet – a collaborative network of key stakeholders working together to address the impact of AMR on human health. It seeks to create an accelerator that will back Australian research into new antimicrobial innovations and to secure investment for a pilot subscription fund for novel antimicrobials to ensure Australians have equitable access to the latest life-saving antibiotics. It also has a dedicated Health and Biosecurity team driving development of dual purpose, advanced medical countermeasures and Defence/National Security related technologies.
Across MTPConnect’s accelerator programs, more than $152 million has been directly injected into the Australian life sciences sector, supporting nearly 200 innovation projects. Its investments have leveraged more than $1.3 billion in additional industry contributions and flow-on external investment, allowing SMEs to scale-up and create new jobs and new medical products.
MTPConnect’s work has seen more than 1,696 new technologies invented or progressed, 374 new products launched and over 746,000 patients treated.
MTPConnect is delighted to lead the Australian delegation at BIO2025 in Boston and work with partners, the state governments of New South Wales, Victoria, Queensland, Western Australia and South Australia, the Department of Industry, Science and Resources, Austrade, CSIRO and AusBiotech.
Leading the Australian Pavilion at BIO2025, MTPConnect is committed to showcasing Australia’s life sciences excellence as a Global Hub for Medical Research, Clinical Trials, and Advanced Manufacturing , globally recognised for fast approval processes, world-class infrastructure, strong IP frameworks and generous tax incentives.
Australia has world-leading health and medical research capability in specialist fields such as oncology, neurology, regenerative medicine, infectious diseases, diabetes, cardiovascular disease and diagnostics.
With a strong ecosystem of start-ups through to manufacturing companies, Australia is uniquely positioned to foster innovative, commercial collaborations with international organisations and is increasingly attractive for investment.
With a team of experts across Australia, MTPConnect can leverage its networks and national reach to make international collaborations a reality.
The MTPConnect team looks forward to connecting and introducing you to the world of life sciences opportunity in Australia.
MTPConnect is headquartered in Melbourne, with teams in Adelaide, Perth, Brisbane and Sydney. Tune in to the MTPConnect Podcast Series to connect with the people and the issues behind Australia’s growing life sciences sector. And connect with the team via LinkedIn and mtpconnect.org.au
